Biodel Inc (BIOD) 0.31 $BIOD
nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman
GlobeNewswire - Wed Jun 01, 4:11AM CDT
nLife Therapeutics, an early-stage biopharmaceutical company leading developments in conjugated nucleic acids as therapeutic agents for central nervous system (CNS) and neuromuscular (NS) disorders, today announced the appointment of Dr. Errol B. De Souza, Ph.D. as executive chairman.
NBIX: 49.02 (+0.44), TRGT: 0.96 (-1.25), CBIO: 1.45 (-0.04), PTN: 0.52 (+0.01), IDXX: 95.13 (+0.17), BIOD: 0.31 (unch)
The Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie
Zacks Equity Research - Zacks Investment Research - Thu May 26, 8:30AM CDT
The Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie
ABBV: 64.65 (+0.49), BIOD: 0.31 (unch), XNPT: 7.07 (+0.05)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 89.71 (+0.75), HZNP: 18.90 (+0.19), ICPT: 154.10 (+2.37), ABBV: 64.65 (+0.49), ACOR: 25.60 (-0.61), BIOD: 0.31 (unch), XNPT: 7.07 (+0.05)
Stock to Watch: Biodel Up 30.7% (BIOD)
Comtex SmarTrend(R) - Wed May 25, 8:50AM CDT
Biodel (NASDAQ:BIOD) is one of today's best performing penny stocks, up 30.7% to $0.50 on 2.6x average daily volume. Biodel has traded 2.7 million shares thus far today, vs. average volume of 1.0 million shares per day. The stock has outperformed the Dow (30.7% to the Dow's 0.6%) and outperformed the S&P 500 (30.7% to the S&P's 0.5%) during today's trading.
BIOD: 0.31 (unch)
Biodel/Albireo Limited to Combine; Focus on Liver Diseases
Zacks Equity Research - Zacks Investment Research - Wed May 25, 8:38AM CDT
Biodel (BIOD) entered into a definitive share exchange agreement to combine with Albireo Limited.
ANIP: 56.41 (-0.10), PFE: 36.21 (+0.09), BMY: 75.38 (+0.10), BIOD: 0.31 (unch)
Biodel Inc. and Albireo Limited Agree to Combine
Marketwired - Tue May 24, 7:05PM CDT
DANBURY, CT and BOSTON, MA--(Marketwired - May 24, 2016) - Biodel Inc. (NASDAQ: BIOD)
BIOD: 0.31 (unch)
AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 55.20 (+0.64), SCMP: 11.38 (-0.11), SCLN: 13.51 (+0.03), BIOD: 0.31 (unch)
Biodel Reports Second Quarter Fiscal Year 2016 Financial Results
Marketwire Canada - Mon May 09, 4:00PM CDT
DANBURY, CT--(Marketwired - May 09, 2016) - Biodel Inc. (NASDAQ: BIOD) today reported financial results for the second fiscal quarter ended March 31, 2016.
BIOD: 0.31 (unch)
Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Lag
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:59PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.33 per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.58 but wider than the year-ago loss of $1.78.
SHPG: 187.85 (-0.36), ICPT: 154.10 (+2.37), BIOD: 0.31 (unch), NKTR: 15.10 (+0.18)
Radius Health (RDUS) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:54PM CDT
Radius Health, Inc. (RDUS) posted a loss of 94 cents per share in the first quarter of 2016, wider than both the Zacks Consensus Estimate of a loss of 83 cents and the year-ago loss of 47 cents
RDUS: 42.76 (+1.51), SHPG: 187.85 (-0.36), BIOD: 0.31 (unch), NKTR: 15.10 (+0.18)
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 79.42 (-0.24), BIOD: 0.31 (unch), CLBS: 0.55 (-0.02), ARGS: 6.39 (+0.15), AZN: 30.04 (-0.07), CGEN: 6.74 (-0.06), ATHX: 2.30 (+0.01)
Type 2 Diabetes Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/82p26k/type_2_diabetes) has announced the addition of the "Type 2 Diabetes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetesand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type 2 DiabetesOverview - Therapeutics Development - Pipeline Products for Type 2 Diabetes- Overview - Pipeline Products for Type 2 Diabetes- Comparative Analysis - Type 2 Diabetes- Therapeutics under Development by Companies - Type 2 Diabetes- Therapeutics under Investigation by Universities/Institutes - Type 2 Diabetes- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type 2 Diabetes- Products under Development by Companies - Type 2 Diabetes- Products under Investigation by Universities/Institutes - Type 2 Diabetes- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - Addex Therapeutics Ltd - Adocia - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - AFFiRiS AG - Alchemia Limited - Alize Pharma SAS - AlphaMab Co., Ltd - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - Amgen Inc. - Anchor Therapeutics, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Arisaph Pharmaceuticals, Inc. - ArisGen SA - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AUS Bio Limited - Avaxia Biologics, Inc. - Bayer AG - Beta-Cell NV - Betagenon AB - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLingus AG - BioRestorative Therapies, Inc. - BioTherapeutics Inc. For more information visit http://www.researchandmarkets.com/research/82...2_diabetes
AMBX: (), AMGN: 160.40 (-0.70), BIOD: 0.31 (unch), AZN: 30.04 (-0.07), ARRY: 3.70 (-0.01)
Conatus Up on Fast Track Status for Emricasan in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 1:40PM CST
Shares of Conatus Pharmaceuticals Inc. (CNAT) soared 22.5% after the company announced that the FDA has granted Fast Track designation to the company's lead pipeline candidate, emricasan,
CNAT: 2.22 (+0.03), CORT: 6.07 (+0.06), PCRX: 36.71 (+0.32), BIOD: 0.31 (unch)
nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman
GlobeNewswire - Wed Jun 01, 4:11AM CDT
nLife Therapeutics, an early-stage biopharmaceutical company leading developments in conjugated nucleic acids as therapeutic agents for central nervous system (CNS) and neuromuscular (NS) disorders, today announced the appointment of Dr. Errol B. De Souza, Ph.D. as executive chairman.
NBIX: 49.02 (+0.44), TRGT: 0.96 (-1.25), CBIO: 1.45 (-0.04), PTN: 0.52 (+0.01), IDXX: 95.13 (+0.17), BIOD: 0.31 (unch)
The Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie
Zacks Equity Research - Zacks Investment Research - Thu May 26, 8:30AM CDT
The Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie
ABBV: 64.65 (+0.49), BIOD: 0.31 (unch), XNPT: 7.07 (+0.05)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 89.71 (+0.75), HZNP: 18.90 (+0.19), ICPT: 154.10 (+2.37), ABBV: 64.65 (+0.49), ACOR: 25.60 (-0.61), BIOD: 0.31 (unch), XNPT: 7.07 (+0.05)
Stock to Watch: Biodel Up 30.7% (BIOD)
Comtex SmarTrend(R) - Wed May 25, 8:50AM CDT
Biodel (NASDAQ:BIOD) is one of today's best performing penny stocks, up 30.7% to $0.50 on 2.6x average daily volume. Biodel has traded 2.7 million shares thus far today, vs. average volume of 1.0 million shares per day. The stock has outperformed the Dow (30.7% to the Dow's 0.6%) and outperformed the S&P 500 (30.7% to the S&P's 0.5%) during today's trading.
BIOD: 0.31 (unch)
Biodel/Albireo Limited to Combine; Focus on Liver Diseases
Zacks Equity Research - Zacks Investment Research - Wed May 25, 8:38AM CDT
Biodel (BIOD) entered into a definitive share exchange agreement to combine with Albireo Limited.
ANIP: 56.41 (-0.10), PFE: 36.21 (+0.09), BMY: 75.38 (+0.10), BIOD: 0.31 (unch)
Biodel Inc. and Albireo Limited Agree to Combine
Marketwired - Tue May 24, 7:05PM CDT
DANBURY, CT and BOSTON, MA--(Marketwired - May 24, 2016) - Biodel Inc. (NASDAQ: BIOD)
BIOD: 0.31 (unch)
AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 55.20 (+0.64), SCMP: 11.38 (-0.11), SCLN: 13.51 (+0.03), BIOD: 0.31 (unch)
Biodel Reports Second Quarter Fiscal Year 2016 Financial Results
Marketwire Canada - Mon May 09, 4:00PM CDT
DANBURY, CT--(Marketwired - May 09, 2016) - Biodel Inc. (NASDAQ: BIOD) today reported financial results for the second fiscal quarter ended March 31, 2016.
BIOD: 0.31 (unch)
Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Lag
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:59PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.33 per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.58 but wider than the year-ago loss of $1.78.
SHPG: 187.85 (-0.36), ICPT: 154.10 (+2.37), BIOD: 0.31 (unch), NKTR: 15.10 (+0.18)
Radius Health (RDUS) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:54PM CDT
Radius Health, Inc. (RDUS) posted a loss of 94 cents per share in the first quarter of 2016, wider than both the Zacks Consensus Estimate of a loss of 83 cents and the year-ago loss of 47 cents
RDUS: 42.76 (+1.51), SHPG: 187.85 (-0.36), BIOD: 0.31 (unch), NKTR: 15.10 (+0.18)
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 79.42 (-0.24), BIOD: 0.31 (unch), CLBS: 0.55 (-0.02), ARGS: 6.39 (+0.15), AZN: 30.04 (-0.07), CGEN: 6.74 (-0.06), ATHX: 2.30 (+0.01)
Type 2 Diabetes Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/82p26k/type_2_diabetes) has announced the addition of the "Type 2 Diabetes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetesand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type 2 DiabetesOverview - Therapeutics Development - Pipeline Products for Type 2 Diabetes- Overview - Pipeline Products for Type 2 Diabetes- Comparative Analysis - Type 2 Diabetes- Therapeutics under Development by Companies - Type 2 Diabetes- Therapeutics under Investigation by Universities/Institutes - Type 2 Diabetes- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type 2 Diabetes- Products under Development by Companies - Type 2 Diabetes- Products under Investigation by Universities/Institutes - Type 2 Diabetes- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - Addex Therapeutics Ltd - Adocia - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - AFFiRiS AG - Alchemia Limited - Alize Pharma SAS - AlphaMab Co., Ltd - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - Amgen Inc. - Anchor Therapeutics, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Arisaph Pharmaceuticals, Inc. - ArisGen SA - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AUS Bio Limited - Avaxia Biologics, Inc. - Bayer AG - Beta-Cell NV - Betagenon AB - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLingus AG - BioRestorative Therapies, Inc. - BioTherapeutics Inc. For more information visit http://www.researchandmarkets.com/research/82...2_diabetes
AMBX: (), AMGN: 160.40 (-0.70), BIOD: 0.31 (unch), AZN: 30.04 (-0.07), ARRY: 3.70 (-0.01)
Conatus Up on Fast Track Status for Emricasan in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 1:40PM CST
Shares of Conatus Pharmaceuticals Inc. (CNAT) soared 22.5% after the company announced that the FDA has granted Fast Track designation to the company's lead pipeline candidate, emricasan,
CNAT: 2.22 (+0.03), CORT: 6.07 (+0.06), PCRX: 36.71 (+0.32), BIOD: 0.31 (unch)
